Immune globulin intravenous (human)-ifas - Biologic Drug Details

✉ Email this page to a colleague

Summary for immune globulin intravenous (human)-ifas

Tradenames:	1
High Confidence Patents:	0
Applicants:	1
BLAs:	1
Suppliers: see list	2

Pharmacology for immune globulin intravenous (human)-ifas

Mechanism of Action	Antigen Neutralization
Physiological Effect	Passively Acquired Immunity
Established Pharmacologic Class	Human Immunoglobulin G
Chemical Structure	Immunoglobulins

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

DrugPatentWatch analysis and brand-side disclosures

These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for immune globulin intravenous (human)-ifas Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for immune globulin intravenous (human)-ifas Derived from DrugPatentWatch Analysis and Company Disclosures

No patents found based on company disclosures

3) Low Certainty: US Patents for immune globulin intravenous (human)-ifas Derived from Patent Text Search

No patents found based on company disclosures

Market Dynamics and Financial Trajectory for the Biologic Drug: Immune Globulin Intravenous (Human)-IFAS

Last updated: July 31, 2025

Introduction

Immune Globulin Intravenous (Human) - IFAS (Intravenous Immune Globulin) is a critical biologic used predominantly in the treatment of primary immunodeficiency disorders, certain autoimmune diseases, and secondary immunodeficiencies. As a high-value therapeutic, its market dynamics and financial trajectory are shaped by multiple factors, including clinical advancements, regulatory environments, demographic trends, and competitive pressures. This comprehensive analysis delineates the current landscape and future trajectory of IFAS, providing insights pertinent to stakeholders and industry participants.

Market Overview and Size

The global immune globulin market was valued at approximately USD 12 billion in 2022 [1], with a compound annual growth rate (CAGR) projected at around 7% through 2030 [2]. The intravenous segment dominates, driven by established formulations like IFAS, which benefits from extensive clinical validation and regulatory approvals.

Market Drivers:

Rising prevalence of primary immunodeficiency diseases (PID), autoimmune disorders such as idiopathic thrombocytopenic purpura (ITP), and neurological conditions like CIDP.
Increased awareness and screening leading to early diagnosis.
Growth in the aging population, which correlates with higher immunodeficiency incidence.
Expanding clinical evidence supporting broader indications.

Market Challenges:

High therapy costs limiting access.
Dependence on plasma-derived raw materials.
Competition from intravenous and subcutaneous formulations, including recombinant products.

Pharmacological Profile and Clinical Indications

IFAS functions primarily as a passive immunization agent, providing pooled immunoglobulin G (IgG) antibodies. Its key indications include:

Primary Immunodeficiency (PID): Replaces missing or deficient IgG antibodies.
Autoimmune Diseases: Used in autoimmune thrombocytopenia (ITP), Kawasaki disease, and certain neurological disorders.
Secondary Immunodeficiency: Post-chemotherapy or post-transplant immunosuppression.

Its efficacy relies on the broad-spectrum antibody component, which confers passive immunity. The safety profile and minimal adverse effects underpin its widespread usage.

Market Dynamics

Regulatory Landscape

Regulatory agencies have upheld stringent standards for plasma-derived products, emphasizing safety, efficacy, and consistency. Recent updates include:

The US Food and Drug Administration’s (FDA) draft guidance on manufacturing standards to ensure plasma safety.
The European Medicines Agency (EMA)’s guidance focusing on plasma collection and traceability.

Regulatory evolutions influence manufacturing investments, product approvals, and market access strategies.

Manufacturing and Supply Chain Considerations

Plasma Collection: Dependent on donor pools; global plasma shortages, Worrisome during COVID-19 pandemic, constrain supply [3].
Manufacturing Complexity: Requires extensive purification and pathogen inactivation steps, impacting costs and scalability.
Emerging Technologies: Recombinant alternatives, though promising, are yet to match the broad immunoprofile of plasma-derived IFAS.

Competitive Landscape

The market features leading players like CSL Behring, Grifols, and Takeda, which dominate global supply. Biosimilar entrants face barriers due to high manufacturing complexity and regulatory requirements.

Pricing and Reimbursement

Prices fluctuate based on regional healthcare policies, with high costs in the U.S. exceeding USD 100,000 annually per patient. Reimbursement dynamics directly impact market penetration and patient access.

Emerging Trends and Future Opportunities

Innovations in Production

Recombinant Immunoglobulins: Potentially reduce dependence on plasma, circumvent supply shortages, and improve safety. However, technical challenges hinder widespread adoption [4].
Enhanced Formulations: Improved stability and traceability; development of subcutaneous variants like Hizentra and Cuvitru offers alternatives with convenience benefits.

Expanding Indications and Off-Label Uses

Ongoing clinical trials explore IFAS’s utility in neurological disorders, chronic inflammatory demyelinating polyneuropathy (CIDP), and other autoimmune conditions, promising new revenue streams.

Personalized Medicine and Biomarkers

Integration of biomarkers may tailor dosing, optimize therapy regimens, and enhance outcomes, positively influencing market growth.

Financial Trajectory

The financial outlook for IFAS reflects a growth trajectory aligned with the broader immune globulin segment. Factors influencing this include:

Market Expansion: Increasing prevalence of immunodeficiencies and autoimmune diseases.
Geographic Penetration: Untapped markets in Asia-Pacific, Latin America, and Middle East present significant growth potential.
Pricing Trends: Moderate price increases driven by inflation and manufacturing costs.

Forecasts suggest the global immune globulin market could surpass USD 20 billion by 2030, with IFAS comprising a substantial share due to its established clinical profile [2].

Market Entry and Investment Considerations

Regulatory Pathways: Submissions for biosimilar versions require comprehensive clinical data; strategic partnerships can facilitate approval.
Manufacturing Scale: Investing in plasma collection infrastructure is critical in ensuring supply and controlling costs.
Intellectual Property: Patents and exclusivity periods influence market entry timing.

Risks and Barriers

Supply Chain Vulnerabilities: Plasma shortages can disrupt production schedules.
Regulatory Hurdles: Stringent approval standards delay market entry for new or biosimilar products.
Pricing Pressures: Healthcare reforms and cost-containment policies may suppress prices.
Competition from Emerging Technologies: Recombinant products and alternative therapies could erode market share.

Key Takeaways

The immune globulin (IFAS) market is poised for continued growth driven by rising disease prevalence, expanding indications, and geographies.
Manufacturing complexities and plasma availability remain significant constraints, influencing supply and pricing.
Innovation, especially in recombinant production and formulation advancements, offers strategic differentiation.
Regulatory and reimbursement dynamics will critically shape future growth and market access.
Stakeholders should prioritize supply chain resilience, product differentiation, and clinical evidence to capitalize on emerging opportunities.

FAQs

Q1: What are the primary factors driving demand for IFAS globally?
A1: Increasing prevalence of immunodeficiency disorders, autoimmune diseases, aging populations, and expanding clinical indications are key drivers of demand.

Q2: How does plasma availability impact the supply of IFAS?
A2: Dependence on donor plasma makes supply vulnerable to shortages, influencing production capacity and pricing.

Q3: Are there technological advancements poised to disrupt the IFAS market?
A3: Yes, recombinant immunoglobulin development could reduce reliance on plasma, although technical and regulatory hurdles remain.

Q4: What regional factors influence the pricing and reimbursement of IFAS?
A4: Healthcare policies, reimbursement frameworks, and market competition vary regionally, affecting pricing and access.

Q5: How might emerging indications affect the future financial trajectory of IFAS?
A5: New approved or off-label uses in neurological and autoimmune conditions can expand the market, driving revenue growth.

Sources

Grand View Research, "Immune Globulin Market Size, Share & Trends Analysis," 2022.
MarketsandMarkets, "Biologic Drugs Market Forecast," 2023.
U.S. FDA, Plasma Supply and Safety Guidelines, 2022.
Jacobson, et al., "Recombinant Immunoglobulin Development Challenges," Journal of Immunology, 2021.

More… ↓

⤷ Get Started Free